Research programme: adoptive cell therapeutics - Immatics

Drug Profile

Research programme: adoptive cell therapeutics - Immatics

Alternative Names: IMA 102; IMA 203; IMA 300; IMA 301

Latest Information Update: 12 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Immatics US
  • Class Antineoplastics; Cell therapies; Immunotherapies; T lymphocyte cell therapies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 11 Oct 2017 Preclinical development is ongoing in USA (Immatics pipeline, October 2017)
  • 30 Sep 2015 Preclinical trials in Cancer in USA (unspecified route) before September 2015
  • 26 Aug 2015 Immatics and The University of Texas MD Anderson cancer centre announced the launch of Immatics US to develop adoptive cell-based therapeutics for Cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top